Bryan Gilburg - China

“The number 1 question we get regarding Chinese registration is regarding clinical evidence. This new guidance provides clarity for many device types on clinical requirements.”

Bryan Gilburg

Managing Director

Come grow with us in the US in Thailand in China in Korea in the Philippines in Taiwan in Hong Kong

Important Documents and Links

Sign Up For Our Newsletter to Stay Informed

China Updates Medical Device Clinical Evaluation Pathway Guidance

Published on: July 29th, 2024

In March of 2024, the Center for Medical Device Evaluation (CMDE) added 25 devices to the “Guidelines for Deciding Whether to Conduct Clinical Trials on Medical Devices” (pdf, original Chinese), originally published in June of 2022.
The guidance provides crucial information to medical device manufacturers wishing to register their products for importation and sales on the Chinese market regarding how to meet the requirements for clinical evidence.

Understanding Clinical Evaluation in China

Clinical evaluation is a critical step in the registration process for medical devices in China. This involves validating whether a medical device meets its intended use requirements or scope of application through clinical literature, clinical experience data, and clinical trials. For all Class II and Class III medical devices, clinical evaluation is mandatory, though requirements vary based on the device’s application scope and associated risks.

NMPA Regulations and Types of Clinical Evaluation

The National Medical Products Administration (NMPA) outlines three types of clinical evaluations:

1. Exemption from Clinical Evaluation:

  • If a product is listed in the “Catalogue of Medical Devices Exempted from Clinical Evaluation,” (pdf, original Chinese) the applicant must submit two comparison tables:
    • One comparing the subject device to the contents described in the Exemption Catalogue.
    • Another comparing the subject device to a similar NMPA-registered device.

2. Clinical Evaluation Report (CER):

  • The applicant should compare the subject device with one or more NMPA-registered predicate devices to demonstrate substantial equivalence (SE). This comparison relies on clinical trials or application data from the predicate devices.

3. Clinical Trials:

  • Conducted by qualified medical institutes, these trials investigate the safety and effectiveness of the subject device under normal conditions.

New Guidance from CMDE: Clinical Evaluation Recommendation Pathways

Registering a medical device in China can be challenging, especially when determining the appropriate registration pathway. If a device is not on the clinical trial exemption list, manufacturers must decide whether to conduct a clinical trial or submit a CER. The “Guidelines for Deciding Whether to Conduct Clinical Trials on Medical Devices” provide some direction, but often, a clinical trial report is still required.

In mid-2022, the China Center for Medical Device Evaluation (CMDE), the technical review authority under the NMPA, issued a comprehensive clinical evaluation recommendation pathway for medical device registration. This pathway is based on China’s Classification Catalogue of Medical Devices and clearly outlines whether a clinical evaluation exemption, CER, or clinical trial is recommended for most devices listed in the catalogue.

Current Status and Recent Developments

To date, the CMDE has provided recommendation pathways for nearly 1,683 types of medical devices. This guidance helps manufacturers identify the correct pathway for their devices, streamlining the registration process.
Listed below are the latest clinical evaluation pathway recommendations issued in March 2024:

SNProduct NameRisk ClassificationRecommendation Pathway
1Surgical Navigation SystemIIICER
2Breast biopsy and rotational cutting system/Breast core biopsy needle and accessoriesIIICER
3Absorbable Hemostatic Ligating ClipIIICER
4Vascular Puncture Closure SystemIIIClinical Trial
5Central Venous Catheter with MedicationIIICER
6Shockwave Therapy DeviceIIICER
7Mechanical Perfusion Trasnport Equipment for Isolated HeartIIIClinical Trial
8Knuckle Prosthesis SystemIIICER
9Wrist Joint Prosthsis SystemIIICER
10Ankle Joint Prosthesis SystemIIICER
11Acrylic Resin Bone Cement Containing MedicationIIIClinical Trial
12Bone Repair MaterialsIIICER
13Femoral Head Necrosis Reconstruction RodIIICER
14Intracranial Drug-Eluting Stent SystemIIIClinical Trial
15Shunt for Hydrocephalus/Cerebrospinal Fluid ShuntIIICER
16Polyvinyl Alcohol Foam Plug ParticlesIIICER
17Left Atrial Appendage Occlusion SystemIIIClinical Trial
18Sodium Hyaluronate Solution for InjectionIIIClinical Trial
19Facial Lifting ThreadIIIClinical Trial
20Implantable Drug Delivery DeviceIIICER
21Hydrogel DressingIIICER
22Collagen PatchesIIICER
23Artificial CorneaIIIClinical Trial
24Dental ImplantIIICER (TiZr) Clinical Trial (Ta)
25Dental Bone Repair MaterialsIIICER

Asia Actual’s regulatory experts in Beijing are available to assist overseas medical device manufacturers to understand and navigate the clinical data requirement for medical device registration in China. Contact us with any questions for support requests.

Blog Posts

Medical Device Registration Processing for Class C and D applications in VietNam is increasing and the backlog beginning to clear

Vietnam Clearing Backlog of Medical Device Registration Applications

Survey of the Vietnam Ministry of Health (MoH) database on May 9, 2024, showed a significant rise in Class C/D medical device processing.
VietNam Allows Legal Document Submission during Registration Application Process

Vietnam Allows Amendments to Registration Applications Under Review

On August 16th, 2024, Vietnam MoH introduced new guidance allowing amendments to registration applications under review, enabling document updates during the process.
VietNam MoH Audits Asia Actual VietName as a License Holder

Vietnam MoH Audits License Holders for Compliance

Asia Actual Vietnam completed an MoH audit, covering key compliance areas including licensing, documentation, and operational procedures.